Clinical Laboratory Molecular Diagnostics Test using inVivoScribe reagents kit.

The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition to Invivoscribe, Inc. for a Clinical Laboratory Molecular Diagnostics Test using inVivoScribe reagents kit. The Molecular Diagnostics Laboratory of the Laboratory of Pathology performs molecular testing to assist in the diagnosis of a variety of cancers. The laboratory develops tests that assist in pathologic diagnosis, predict prognosis, and identify potential targets for rational personalized therapies. The contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2026-01. Some key points about this opportunity include: • The contract is for a non-competitive procurement • The intended procurement is classified under NAICS code 541990 • The contract will not exceed the simplified acquisition threshold of $350,000 • The contract is exempt from the requirements of FAR Part 6-Competition Requirements • Interested parties may identify their interest and capability to respond to this notice • Responses must be received by June 29, 2026, at 9:00 AM Eastern time